Galapagos and Alfasigma S.p.A. announced that they have signed an agreement to transfer Galapagos? Jyseleca® (filgotinib) business to Alfasigma, marking a significant milestone in Galapagos? transformation into an innovative biotechnology company with a best-in-class research and development pipeline aimed at addressing high unmet patient needs in immunology and oncology.

The agreement follows the signing of a letter of intent as announced on 30 October 2023. Subject to, and as part of the closing of the transaction, Michele Manto, Galapagos? Chief Commercial Officer, will join Alfasigma, and has resigned from his position as Chief Commercial Officer and Executive Committee member at Galapagos at the end of December 2023.